Get the Stockscreener App
424.24
0.57%
-2.42
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $424.24, with a volume of 2.70M.
It is down -0.57% in the last 24 hours and down -17.52% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
See More
Previous Close:
$426.66
Open:
$426.12
24h Volume:
2.70M
Relative Volume:
1.28
Market Cap:
$159.25B
Revenue:
$42.90B
Net Income/Loss:
$6.52B
P/E Ratio:
24.88
EPS:
17.05
Net Cash Flow:
$6.72B
1W Performance:
-0.76%
1M Performance:
-17.52%
6M Performance:
-23.47%
1Y Performance:
-25.80%
1-Day Range:
$416.82
$426.72
1-Week Range:
$416.62
$461.61
52-Week Range:
$409.85
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
424.24 | 159.25B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.14 | 132.37B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
437.44 | 32.95B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
106.28 | 28.58B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.28 | 24.90B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Next-Generation Sequencing (NGS) Data Analysis Market to Hit USD 4.21 Billion by 2032, Driven by Rising Genomic Research and Precision Medicine Initiatives – SNS Insider - GlobeNewswire Inc.
Thermo Fisher commits $2B to US manufacturing - Manufacturing Dive
Thermo Fisher to invest $2 B over next 4 years to enhance innovation in US - BioSpectrum Asia
Cell Separation Market to Witness Remarkable Growth with Thermo - openPR.com
Gene Panel Market Set to Witness Significant Growth by 2025-2032 - openPR.com
Thermo Fisher to invest $2bn to strengthen US healthcare supply chain - World Pharmaceutical Frontiers
Thermo Fisher Scientific Reports First Quarter 2025 Results - ADVFN
Thermo Fisher counters tariffs with $2bn investment into US manufacturing - Pharmaceutical Technology
Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan - Benzinga
Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending - Fierce Pharma
Thermo Fisher Scientific (NYSE:TMO) Completes US$3 Billion Buyback and Reports Rising Q1 Earnings - Yahoo Finance
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
Thermo Fisher releases single-use bioreactor - Scientist Live
Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers’ Manufacturing - BioSpace
Microplate Readers Market to Witness Massive Growth by 2032 | Thermo Fisher Scientific, Inc., PerkinElmer, Inc - openPR.com
Fund Update: Waverton Investment Management Ltd added 52,324 shares of THERMO FISHER SCIENTIFIC ($TMO) to their portfolio - Nasdaq
UBS Lowers Price Target for Thermo Fisher (TMO) Due to Macro Cha - GuruFocus
3 Healthcare Stocks with Mounting Challenges - Yahoo Finance
Thermo Fisher To Invest Addl. $2 Bln In U.S. To Boost Manufacturing - Nasdaq
Thermo Fisher to invest $2 billion in U.S. operations By Investing.com - Investing.com Australia
Thermo Fisher to Spend $2 Billion to Expand U.S. Presence - marketscreener.com
Thermo Fisher to Invest Additional $2 Billion in US Over Next 4 Years - marketscreener.com
Thermo Fisher Scientific: Tariff And Policy Impacts Look Priced In - Seeking Alpha
Thermo Fisher Scientific First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Thermo Fisher Scientific’s revenue increases 1% in Q1 2025 - Medical Buyer
Thermo Fisher Scientific Inc (TMO) Q1 2025 Earnings Call Highlights: Strong Financial ... - Yahoo Finance
Thermo Fisher cuts 2025 profit forecast on tariff hit, research funding cuts - MSN
Thermo Fisher Scientific Inc (TMO) Q1 2025 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Thermo Fisher Scientific receives the Key to Gothenburg - Cision News
Thermo Fisher Scientific Reports Strong Q1 2025 Results - TipRanks
Thermo Fisher Scientific building hangar at Pease: Will more follow? - Seacoastonline.com
Tariffs expected to hurt Thermo Fisher results - WFMZ.com
Thermo Fisher Scientific Navigates Strong Q1 Amid Challenges - TipRanks
Goldman Sachs Adjusts Price Target for Thermo Fisher (TMO), Main - GuruFocus
Thermo Fisher Beats Q1 Estimates, Lowers Full-Year Forecast As Tariffs And Costs Take A Toll - Benzinga
Thermo Fisher: Q1 Earnings Snapshot - Milford Mirror
Thermo Fisher invests $2B in US to counter tariffs, funding cuts - The Business Journals
Antimicrobial Susceptibility Testing Size, Share & Trends - openPR.com
Thermo Fisher Reports Strong Q1 Earnings But Revises Full-Year Guidance In Light Of Trump Tariffs: Retail’s Pessimistic By Stocktwits - Investing.com India
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up - Yahoo Finance
Thermo Fisher updates 2025 revenue guidance to $43.3B-$44.2B amid macroeconomic challenges - MSN
Thermo Fisher Tops Q1 Estimates in 'Uncertain Macroeconomic Environment' - Investopedia
Thermo Fisher Tops Expectations With High Demand For Research Tools - Finimize
Why Thermo Fisher Scientific Inc. (TMO) is Among the Best Stocks That Will Always Grow - Insider Monkey
Earnings call transcript: Thermo Fisher Q1 2025 beats EPS forecast, stock rises - Investing.com
Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire - Investopedia
Thermo Fisher Scientific Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Thermo Fisher Cuts 2025 Profit Forecast on Tariff Hit, Research Funding Cuts - Money/ US News
Thermo Fisher beats estimates on steady demand for tools and services used in clinical research - TradingView
Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Thermo Fisher Scientific tops Q1 estimates, shares rise - Baystreet.ca
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):